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doi:10.1016/j.jfma.2011.02.006Background/Purpose: This study evaluated the immune response elicited by two formulations
of an AS03A-adjuvanted H5N1 A/Indonesia/05/2005 prepandemic influenza vaccine, developed
using manufacturing processes with or without thiomersal. In addition, it also evaluated
compliance to the Centre for Biologics Evaluation and Research and Committee for Medicinal
Products for Human Use (CHMP) immunogenicity guidance criteria for pandemic influenza
vaccines in adults.
Methods: This phase III, observer-blind, randomized study (NCT00812981) enrolled 320
subjects aged 1860 years into two groups to receive, 21 days apart, two doses of the formu-
lation manufactured using either the thiomersal-containing process (Group TC) or the
thiomersal-free process (Group TF). Blood samples collected before vaccination, 21 days after
the second vaccine dose, and 6 months following the first vaccine dose (Days 0, 42, and 180)
were analysed using a hemagglutination inhibition (HI) assay. Safety assessments were made
for the entire study period.
Results: Twenty-one days after the second dose of vaccine, both groups met the CHMP criteria
for vaccine-homologous HI response (seroprotection rates/seroconversion rates  98.7%, sero-
conversion factor  121.9) and also for a heterologous HI response against the A/Vietnam/
1194/2004 strain (seroprotection rates/seroconversion rates  81.3%, seroconversion factor
 10.8). Six months after the first dose of vaccine, a marked persistence of the vaccine-
homologous HI response was observed that still met one or more CHMP criteria. Pain at the
injection site (Group TF 95%, Group TC 91.8%) and myalgia (Group TF 68.8%, Group TCiwan University Hospital, 7 Chung San South Road, Taipei 100, Taiwan.
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334 P.-C. Yang et al.63.5%) were the most frequently recorded solicited symptoms. Overall, both formulations had
a clinically acceptable safety profile.
Conclusion: Administration of two doses of the AS03A-adjuvanted H5N1 prepandemic influenza
vaccine was found to be highly immunogenic in adults with a clinically acceptable safety profile.
The ability to confer cross-clade protective immunity makes it a suitable option for mitigation of
the morbidity and mortality of outbreaks and pandemics due to H5N1 and drifted strains.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Since its re-emergence in 2003, the H5N1 influenza virus
has caused more than 500 laboratory-confirmed cases and
300 deaths worldwide.1 The H5N1 virus continues to be
a persistent threat despite its limited ability for human-to-
human transmission, and has the potential to cause
a pandemic by itself.2
Timely vaccination is considered to be the most effec-
tive intervention against morbidity and mortality caused by
an influenza pandemic.3e5 A monovalent, split-virion H5N1
influenza vaccine adjuvanted with AS03A [a tocopherol oil-
in-water emulsion-based adjuvant system; Prepandrix,
GlaxoSmithKline (GSK) Biologicals, Wavre, Belgium] has
been shown to be highly immunogenic, with a clinically
acceptable safety profile.6e9 A previous multicenter study
with this vaccine (with A/Vietnam/1194/2004 NIBRG-14
strain Clade 1) in a large Asian population demonstrated
robust immune responses against vaccine-homologous and
vaccine-heterologous strains, coupled with a clinically
acceptable safety profile.6
The present study in a Taiwanese population evaluated
the immune response elicited by two formulations of an
AS03A-adjuvanted H5N1 prepandemic influenza vaccine
with A/Indonesia/05/2005 IBCDC-RG2 Clade 2.1 strain,
developed using either a thiomersal-free or a thiomersal-
containing process. The final presentation of both formu-
lations was in multidose vials and contained thiomersal as
a preservative. The study also evaluated compliance with
the European Committee for Medicinal Products for Human
Use (CHMP) and the US Food and Drug Administration’s
Centre for Biologics Evaluation and Research (CBER)
immunogenicity guidance criteria for pandemic influenza
vaccines in adults and the long-term persistence of an
immune response (6 months following the first dose)
following two vaccine doses.
Materials and methods
Study design and participants
This phase III, observer-blind, randomized study
(NCT00812981) was conducted at the National Taiwan
University Hospital between November 15, 2008 and June
7, 2009. Healthy subjects aged 18e60 years were
randomized using an allocation ratio of 1:1 into two groups
to receive two doses of one of the two formulations of the
AS03A-adjuvanted H5N1 prepandemic influenza vaccine, 21
days apart. This was either the formulation developed
using a thiomersal-containing manufacturing process
(Group TC) or the formulation developed usinga thiomersal-free process (Group TF). Treatment allocation
was carried out using an Internet-based central randomi-
zation system (SBIR) that used a minimization procedure
accounting for center (The SBIR application is developed
in-house by GSK).
The subjects and study personnel evaluating the safety
and immunogenicity end-points were blinded. Study
personnel responsible for vaccine preparation and admin-
istration were not blinded but were not involved in the
evaluation of the end-points. The laboratories were blinded
to treatment assignment.
Volunteers were not eligible if they had previously
received any H5N1 vaccine or oil-in-water adjuvanted
vaccine; in addition, volunteers who received any vaccine
investigational product within 30 days prior to vaccination,
presented suspected or confirmed immunosuppressive
conditions, received immunoglobulins within 3 months of
the study start, or had a history of allergic reactions to any-
of the constituents of influenza vaccines were also excluded.
Written informed consent was obtained from all subjects
prior to conducting any study-related procedures. The
study was conducted in accordance with good clinical
practice, the Declaration of Helsinki, and all relevant local
regulations. All study-related documents and procedures
were approved by the appropriate ethics committees.
Study vaccines
The study vaccines were developed and manufactured by
GSK Biologicals. Each dose of the formulation developed
using the thiomersal-containing process (Prepandrix,
0.5 mL) and the one developed using the thiomersal-
free process contained 3.75 mg hemagglutinin of the
A/Indonesia/05/2005 IBCDC-RG2 Clade 2.1 strain (National
Institute for Biological Standards and Control, Potters Bar,
UK) adjuvanted with AS03A [a tocopherol oil-in-water
emulsion-based adjuvant system (11.86 mg tocopherol)].
As both formulations were available in multidose vials,
thiomersal was added as a preservative. Vaccines were
administered intramuscularly into the deltoid muscle of the
nondominant arm.
Laboratory assays and immunogenicity assessments
Antibody titers were measured using a standardized and
validated microassay using 4 hemagglutination-inhibiting
units of the appropriate antigens and a 0.5% horse eryth-
rocyte suspension. After an initial dilution of 1:10, the
serum samples were serially diluted by twofold. Nonspecific
serum inhibitors were removed by heat treatment and
receptor-destroying enzyme.
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days after the second vaccine dose, and 6 months following
the first vaccine dose (Days 0, 42, and 180, respectively).
Geometric mean titers (GMTs), seroprotection rates, sero-
conversion rates, and seroconversion factors in terms of
hemagglutination inhibition (HI) antibodies against the
homologous A/Indonesia/05/2005 IBCDC-RG2 strain and
heterologous A/Vietnam/1194/2004 NIBRG-14 strain were
assessed, with 95% confidence intervals (CIs).
The immunogenicity cut-offs (seroprotection rates
> 70%, seroconversion rates > 40%, and seroconversion
factor > 2.5) were based on the CHMP criteria for the
licensure of pandemic influenza vaccines in adults (aged
18e60 years).10,11
Safety and reactogenicity assessments
Subjects used diary cards to record the occurrence and
intensity of solicited local and general adverse events up to
7 days following each vaccine dose. All unsolicited adverse
events were recorded up to 21 days after the first dose and
30 days after the second dose. Serious adverse events
(SAEs) were recorded up to 6 months following the first
dose.
The intensity of solicited symptoms was graded on
a standard scale of 0e3 (except fever, which was graded
on a scale of 0e4), with Grade 3 symptoms being those
that prevented normal daily activities. Grade 3 redness
and swelling were defined as those with a diameter of
> 100 mm; Grade 3 fever was defined as temperatures
 39.0e40.0 C ( 102.2e104.0 F), while Grade 4 fever
was defined as temperatures > 40.0 C (> 104.0 F). An
assessment of causality was made by the investigator for all
reported adverse events except for solicited local symp-
toms, which were assumed to be vaccine-related.
Statistical analyses
The primary objective of this study was to demonstrate the
immunological noninferiority (in terms of H5N1 HI antibody
GMTs) between the two vaccine formulations, 21 days after
second the second vaccine dose in healthy adults; the
criterion for meeting the noninferiority objective was the
upper limit of two-sided 95% CI of the GMT ratio (Group TC
over Group TF) < 2 in terms of HI antibody titer against the
A/Indonesia/05/2005 strain. The sample size was calcu-
lated taking into consideration the primary objective. A
total of 304 evaluable subjects (152 subjects per group)
were estimated to provide at least 99% power to reach the
primary end-point. Accounting for approximately 5% of
subjects to be nonevaluable, it was planned to enroll 320
subjects (160 per group). The secondary objective of the
study was to evaluate whether the two vaccine formula-
tions could elicit HI antibody responses that could fulfill the
CHMP and CBER immunogenicity guidance criteria, 21 days
after the second vaccine dose.10,11
The seroconversion rate was defined as the proportion
of subjects with a prevaccination HI titer< 1:10 and
a postvaccination titer 1:40, or a prevaccination HI
titer> 1:10 and a fourfold increase in postvaccination
titer. The seroprotection rate was defined as theproportion of subjects with a postvaccination HI
titer 1:40, and seroconversion factor as the fold increase
in serum HI antibody GMTs postvaccination compared to
that prior to vaccination.
The primary analyses of immunogenicity were performed
on the according-to-protocol (ATP) cohort for immunoge-
nicity, and the analyses of safety were performed on the
total vaccinated cohort.
All statistical analyses were performed using Statistical
Analyses System (SAS) version 9.1 (SAS, North Carolina,
USA), while all 95% CI for proportions within a group were
calculated using Proc StatXact 5.0 (Cytel Inc., Massachu-
setts, USA). The GMT ratios with their 95% CIs were
obtained using an analysis of covariance (ANCOVA) model
on the logarithm-transformed titers. The ANCOVA model
included the vaccine group as fixed effect and the log-
prevaccination concentration/titers as regressors.Results
Demographic characteristics
A total of 320 subjects were enrolled, equal numbers of
subjects (160 subjects each) receiving at least one dose of
the formulation developed using either the thiomersal-
containing process (Group TC) or the thiomersal-free
process (Group TF). The ATP cohort for immunogenicity at
Day 42 included 156 subjects from each group, while the
ATP cohort for persistence at Day 180 included 155 subjects
from each group. The reasons for elimination from analyses
at Day 42 and Day 182 are presented in Fig. 1.
The mean age of the subjects at the time of first
vaccination was 31.9 years (standard deviation 8.56 years,
range 18e58 years). The study population was balanced for
gender (male to female ratio 49.1: 50.9). All subjects were
of East Asian heritage.
Immune response
Primary objective
The primary objective of the study was met, the results
demonstrating the immunological noninferiority (in terms
of H5N1 HI antibody GMTs) of Group TF compared to Group
TC, 21 days after the second vaccine dose in healthy
Taiwanese adults aged 18e60 years (GMT ratio 0.84,
confidence interval: 0.710.99).
Immunogenicity against the homologous A/Indonesia/05/
2005 IBCDC-RG2 strain
Before vaccination, < 2% of subjects in both groups had HI
antibodies  1:10. Twenty-one days after the second
vaccine dose, more than 98.7% of subjects in both groups
showed seroconversion and seroprotection, the HI antibody
GMTs in the two groups being 739.5 and 621.7 for Group TF
and Group TC, respectively (Table 1).
Six months following the first vaccine dose, 82.6% of
subjects in Group TF and 67.1% of subjects in Group TC
continued to have titers of  1:40 against the vaccine-
homologous strain; the corresponding HI antibody GMTs
were comparable (52 and 33, respectively).
Figure 1 CONSORT diagram: Subject flow through the phases of the trial. See text for abbreviations.
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1194/2004 NIBRG-14 strain
Before vaccination, < 2% of subjects in both groups had HI
antibodies  1:10. Twenty-one days after the second
vaccine dose, 91.7% of subjects in Group TF and 81.3% of
subjects in Group TC had seroconverted, and HI antibody
GMTs in the two groups were 79.7 and 56.1, respectively
(Table 1).
Six months following the first vaccine dose, 21.9% of
subjects in Group TF and 10.3% of subjects in Group TC
continued to have putatively seroprotective HI titers
against the vaccine-heterologous strain; the corresponding
HI antibody GMTs were comparable (12.7 and 8.4,
respectively).CHMP criteria
The secondary immunogenicity objective in terms of H5N1
HI antibody was met as both formulations of the AS03A-
adjuvanted H5N1 vaccine elicited robust immune responses
at Day 42 that exceeded the immunogenicity guidance
criteria of the CHMP for licensure of pandemic influenza
vaccines in adults.10 In addition, the more stringent licen-
sure criteria for pandemic influenza vaccines from the CBER
(lower boundary of 95% CI for seroprotection rate and
seroconversion rate  70% and  40%, respectively) were
also met.11 Six months after the first vaccine dose (Day
180), the CHMP and CBER criteria were met by Group TF in
terms of HI antibodies against the A/Indonesia/05/2005IBCDC-RG2 strain, while Group TC failed to meet the
criteria for seroprotection rate; neither of the groups met
any of the criteria for the A/Vietnam/1194/2004 NIBRG-14
strain at this time point.Safety and reactogenicity
Overall, the incidences of solicited local and general
symptoms during the 7-day postvaccination follow-up
period were similar in both groups. Pain at the injection
site (Group TF 95%, Group TC 91.8%) and myalgia (Group TF
68.8%, Group TC 63.5%) were the most frequently recorded
solicited symptoms (Table 2). Grade 3 pain was reported by
7.5% of individuals. The incidences of solicited local and
general symptoms were observed to have a similar trend
following each dose of the two vaccine formulations.
Overall, 30.6% of subjects in Group TF and 33.1% of
subjects in Group TC reported at least one unsolicited
adverse event. The most frequently reported unsolicited
symptoms in the two groups were nasopharyngitis (10% and
11.9%, respectively, in Groups TF and TC) and phar-
yngolaryngeal pain (4.4% and 3.8%, respectively, in Groups
TF and TC). Unsolicited symptoms that were considered by
the investigator to be causally related to vaccination were
recorded in 9.4% of subjects in Group TF and 7.5% of
subjects in Group TC. A total of six SAEs was recorded
during the entire study period (two in Group TF and four in
Group TF). None of the SAEs was considered by the inves-
tigator to be causally related to vaccination.
Table 1 Immune response induced by the two formulations of the AS03A-adjuvanted H5N1 vaccine against the vaccine-
homologous A/Indonesia/05/2005 IBCDC-RG2 strain and vaccine-heterologous A/Vietnam/1194/2004 NIBRG-14 strain, 21 days
after dose 2 and 6 months after dose 1 (according-to-protocol cohort for immunogenicity and persistence).
Strain Immunogenicity criteria
(CHMP criteria)
Time
point
Group TF % (95% CI) Group TC % (95% CI)
HI antibody response
A/Indonesia/05/2005
IBCDC-RG2
Seroprotection ratea
(point estimate > 70%)
Pre 0.0 (0.02.3) 0.0 (0.02.3)
D42 100 (97.7100) 98.7 (95.499.8)
D180 82.6 (75.788.2) 67.1 (59.174.4)
Seroconversion rateb
(point estimate > 40%)
D42 100 (97.7100) 98.7 (95.499.8)
D180 82.6 (75.788.2) 67.1 (59.174.4)
Seroconversion factorc
(point estimate > 2.5)
D42 147.9 (133.6163.8) 121.9 (106.3139.7)
D180 10.4 (9.012.0) 6.5 (5.57.6)
Geometric mean titer Pre 5.0 (5.05.0) 5.1 (5.05.2)
D42 739.5 (667.8818.8) 621.7 (542.9712.0)
D180 52.0 (45.159.9) 33.0 (28.039.0)
A/Vietnam/1194/2004
NIBRG-14
Seroprotection ratea
(point estimate > 70%)
Pre 0.6 (0.03.5) 1.9 (0.45.5)
D42 92.3 (86.996.0) 81.9 (75.087.6)
D180 21.9 (15.729.3) 10.3 (6.016.2)
Seroconversion rateb
(point estimate > 40%)
D42 91.7 (86.295.5) 81.3 (74.287.1)
D180 21.9 (15.729.3) 8.4 (4.513.9)
Seroconversion factorc
(point estimate > 2.5)
D42 15.6 (13.517.9) 10.8 (9.112.7)
D180 2.5 (2.12.9) 1.6 (1.41.8)
Geometric mean titer Pre 5.1 (4.95.3) 5.2 (5.05.5)
D42 79.7 (69.491.5) 56.1 (47.666.0)
D180 12.7 (10.814.8) 8.4 (7.39.5)
CHMPZ Committee for Medicinal Products for Human Use; CIZ confidence interval; GMTZ geometric mean titer; HIZ hemaggluti-
nation inhibition; PreZ before vaccination.
a Seroprotection rate was defined as post-vaccination HI antibody titer  1:40.
b Seroconversion rate was defined as pre-vaccination HI antibody titer < 1:10 and post-vaccination HI antibody titer  1:40, or pre-
vaccination HI antibody titer  1:10 and at least a four-fold increase in HI antibody titer post-vaccination.
c Seroconversion factor was defined as the fold increase in HI antibody GMTs post-vaccination compared to the GMT before
vaccination.
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Following the A/H1N1 2009 pandemic, there has been
a shift in the picture of influenza strains circulating
worldwide. The recent influenza-like-illnesses recorded in
different regions have been attributed to the dominant
strains A/H3N2 and A/H1N1 2009, and a few to influenza
B.12,13 However, the H5N1 avian influenza continues to
circulate in poultry in Asian and north-east African coun-
tries, and minimal poultry-to-human or human-to-human
transmission has been reported (the current World Health
Organization pandemic alert for H5N1 avian influenza being
3); however, sporadic outbreaks continue to be reported
in some countries in South-East Asia.12 The H5N1 viruses
associated with human infection have diversified both
genetically and antigenically.14 A continuous evaluation of
postvaccination crossreactive antibodies against newly
emerging strains is critical to evaluate the broadness ofimmunity induced by present H5N1 vaccines. A good
collaboration between influenza surveillance laboratories
and vaccine manufacturers is essential to develop an effi-
cient reactive testing process when emerging antigenically
variant strains are identified.
This is one of the first studies to be conducted with this
AS03A-adjuvanted H5N1 prepandemic vaccine containing
the A/Indonesia/05/2005 strain in an Asian population.
The results have confirmed that two doses of this vaccine
can elicit robust immune responses against both vaccine-
homologous and vaccine-heterologous strains, which is
compliant with the CHMP and CBER immunogenicity guid-
ance criteria for pandemic influenza vaccines. These
results are in agreement with a previous Asian study with
a Taiwanese subcohort using the same vaccine with the
H5N1 A/Vietnam/1194/2004 strain, in which the immune
response elicited by the vaccine against vaccine-
homologous and vaccine-heterologous strains met the
Table 2 Solicited local and general symptoms reported
following vaccination with both formulations of the AS03A-
adjuvanted H5N1 vaccine during the 7-day postvaccination
follow-up periods (total vaccinated cohort).
Solicited
symptoms
Severitya Group TF
NZ 160
% (95% CI)
Group TC
NZ 159b
% (95% CI)
Local
Pain All 95.0 (90.497.8) 91.8 (86.495.6)
Grade 3 7.5 (3.912.7) 5.0 (2.29.7)
Redness All 2.5 (0.76.3) 3.1 (1.07.2)
Grade 3 0.0 (0.02.3) 0.0 (0.02.3)
Swelling All 13.1 (8.319.4) 11.9 (7.418.0)
Grade 3 0.0 (0.02.3) 1.3 (0.24.5)
General
Arthralgia All 20.0 (14.127.0) 20.8 (14.727.9)
Grade 3 1.3 (0.24.4) 1.3 (0.24.5)
Fatigue All 65.0 (57.172.4) 62.3 (54.269.8)
Grade 3 5.6 (2.610.4) 3.8 (1.48.0)
Headache All 36.9 (29.444.9) 42.8 (35.050.8)
Grade 3 2.5 (0.76.3) 2.5 (0.76.3)
Myalgia All 68.8 (61.075.8) 63.5 (55.571.0)
Grade 3 5.0 (2.29.6) 3.1 (1.07.2)
Shivering All 10.0 (5.815.7) 8.8 (4.914.3)
Grade 3 1.3 (0.24.4) 0.0 (0.02.3)
Sweating All 10.0 (5.815.7) 11.3 (6.817.3)
Grade 3 0.0 (0.02.3) 0.0 (0.02.3)
Fever All 6.3 (3.011.2) 10.1 (5.915.8)
Grade 3 0.6 (0.03.4) 1.3 (0.24.5)
Grade 4 0.0 (0.02.3) 0.0 (0.02.3)
NZ Number of subjects with at least one documented dose;
CIZ Confidence interval.
a Grade 3Z pain at injection site that hindered normal daily
activities; injection site redness, swelling, ecchymosis and
induration > 100 mm; fever > 39 C and up to 40 C; other
solicited general symptoms that hindered normal day-to-day
activities. Grade 4Z fever > 40 C.
b One subject in the TC group did not comply with the
completion/collection of reactogenicity data using the diary
card, hence only 159 subjects “with available data at Days 21,
42, and 182” were used as the denominator.
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also concur with immunogenicity data on the study vaccine
in other populations.7e9
Further, the study also corroborates previous results on
the persistence of the HI response at 6 months after
vaccination, a noticeable response level against the
vaccine-homologous strain still being observed. The decline
of the vaccine-homologous immune response over time is
not an unexpected finding and is in line with persistence
results obtained in other trials of the H5N1 vaccines (with
A/Indonesia or A/Vietnam strain). It is important to note
in this context that strong booster responses have been
observed in two prime-boost clinical trials15,16 upon
revaccination with a homologous or heterologous AS03-
adjuvanted H5N1 vaccine up to 15 months after primary
vaccination, i.e. at a time point when the HI antibody
levels had returned to low levels. Thus, despite theobserved decline in HI antibody levels, there is evidence of
persistence of immune memory. Lower levels of seropro-
tection were nevertheless observed against the vaccine-
heterologous strain at 6 months (21.9% and 10.3% in
Group TF and Group TC, respectively), but previous
observations reported on the possibility of boosting this
response up to 14 months after primary vaccination.15,16
Although the study population in the current study was
not as large or diverse as in the Asian study by Chu et al,6
the present study provides evidence that, irrespective of
the strain used, the vaccine is highly immunogenic with
a clinically acceptable safety profile in adults. This flexi-
bility gives an opportunity to update the vaccine with the
H5N1 strain made available by the World Health Organiza-
tion for inclusion in the H5N1 vaccines.17 It was beyond the
scope of the current study to evaluate whether the immu-
nogenicity of the vaccine was influenced by the age of the
recipients. However, previous studies have demonstrated
that the 3.75 mg HA AS03A-adjuvanted H5N1 vaccine eli-
cited broad and persistent immune responses in elderly
individuals and children.18,19 Thus, this vaccine can be
a suitable option for mitigating the morbidity and mortality
of outbreaks and pandemics due to H5N1 and drifted
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